Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.
Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.
复制标题
DOI：
10.18632/oncotarget.9172
复制
发表时间：
2016-05-31
期刊：
影响因子：
--
通讯作者：
Carnero A
中科院分区：
文献类型：
--
作者：
de Miguel-Luken MJ;Chaves-Conde M;Quintana B;Menoyo A;Tirado I;de Miguel-Luken V;Pachón J;Chinchón D;Suarez V;Carnero A
目前的保喉治疗已经取得了改善喉-食道无功能生存(LDS)的效果，但会导致严重的毒性反应和复发。目前，没有证据表明选择哪组患者可能会从保存方法而不是手术中受益。因此，喉部生物标志物有助于对化疗-放射治疗有反应的患者进行预识别。在这项研究中，我们对53例喉癌患者进行了回顾性评估，以确定gH2 AX磷酸化(PH2AX)单独或与膜蛋白MAP17(PDZK1IP1)联合作为预后生物标志物。我们还评估了顺铂治疗和放射治疗的完成与PH2AX联合应用是否能预测生存率。我们发现，接受顺铂的剂量而不是放射治疗的长度会影响LDS。PH2AX高表达与LDS延长相关(HR 0.26，p=0.02)，而MAP17表达与总生存期(OS)相关(HR 0.98，p=0.05)。高MAP17和高PH2AX联合分析显示LDS(61.35个月比32.2个月，p=0.05)和OS(66.6个月比39.8个月，p=0.01)有所改善。此外，高PH2AX和最佳顺铂剂量组还与OS(72个月比38.6月，P=0.03)和LDS(66.9月比27个月，P=0.017)相关。这些发现表明，PH2AX单独或更好地与MAP17联合应用可能成为喉癌保留治疗患者的一种新的、有价值的预后生物标志物。
Current larynx preservation treatments have achieved an improvement of laryngoesophageal dysfunction-free survival (LDS) but lead to significant toxicities and recurrences. At present, there is no evidence to select the group of patients that may benefit from preservation approaches instead of surgery. Therefore, laryngeal biomarkers could facilitate pretreatment identification of patients who could respond to chemoradiation-based therapy. In this study, we evaluated retrospectively 53 patients with larynx cancer to determine whether gH2AX phosphorylation (pH2AX) alone or in combination with the membrane protein MAP17 (PDZK1IP1) could be used as prognostic biomarkers. We also evaluated whether the completion of cisplatin treatment and radiotherapy could predict survival in combination with pH2AX. We found that the dose of cisplatin received but not the length of the radiotherapy influenced LDS. High-pH2AX expression was associated with prolonged LDS (HR 0.26, p = 0.02) while MAP17 correlated with overall survival (OS) (HR 0.98, p = 0.05). High-MAP17 and high-pH2AX combined analysis showed improved LDS (with 61.35 months vs 32.2 months, p = 0.05) and OS (with 66.6 months vs 39.8 months, p = 0.01). Furthermore, the subgroup of high-pH2AX and optimal dose of cisplatin was also associated with OS (72 months vs 38.6 months, p = 0.03) and LDS (66.9 months vs 27 months, p = 0.017). These findings suggest that pH2AX alone or better in combination with MAP17 may become a novel and valuable prognostic biomarker for patients with laryngeal carcinoma treated with preservation approaches.
登录
查看更多内容
影响因子：
64.8
作者：
Bartkova, J;Horejsi, Z;Bartek, J
通讯作者：
Bartek, J
DOI：
10.18632/aging.100443
发表时间：
2012-03
期刊：
Aging
影响因子：
--
作者：
Blagosklonny MV
通讯作者：
Blagosklonny MV
DOI：
10.18632/aging.100422
发表时间：
2011-12
期刊：
Aging
影响因子：
--
作者：
Blagosklonny MV
通讯作者：
Blagosklonny MV
影响因子：
4.3
作者：
Blagosklonny, Mikhail V.
通讯作者：
Blagosklonny, Mikhail V.
DOI：
10.1007/978-1-62703-239-1_4
发表时间：
2013-01-01
期刊：
Methods in molecular biology (Clifton, N.J.)
影响因子：
--
作者：
Carnero, Amancio
通讯作者：
Carnero, Amancio